Acinetobacter spp. are uncommon etiologic agents of prosthetic valve endocarditis. Two patients with Acinetobacter calcoaceticus subsp. lwoffi prosthetic valve endocarditis are described. The patients were successfully treated with antibiotics (cefotaxime sodium and gentamicin sulfate); thus, we suggest medical treatment rather than early valve replacement in this particular type of infection.
by A. calcoaceticus subsp. lwoffi successfully treated with antibiotics (cefotaxime sodium and gentamicin sulfate) are reported.
Case reports. Patient 1. A 47-year-old man was admitted for evaluation of fever up to 38°C which developed 1 month before admission. Six weeks before admission the patient was involved in a road accident with multiple lacerations and was treated with oral ampicillin sodium. Fourteen years before he had undergone an aortic valve replacement (McGovern valve) for severe aortic stenosis (congenital bicuspid aortic valve). On physical examination his body weight was 69 kg, his temperature was 38°C, and he had a regular heart rate of 90 beats per min and blood pressure of 110/70. Few raies were heard over the lung bases. An early diastolic murmur grade 2/6 was heard at the lower left sternal border. There were no splenomegaly, purpura, petechiae, or signs of peripheral embolization. The erythrocyte sedimentation rate was 78 mm in the first hour, the hemoglobin concentration was 12.9 g/dl, and the leukocyte count was 5,800/mm3 with 70% neutrophils. Liver work.
Blood cultures were performed with tryptic soy broth and thioglycolate broth (30-ml, model 6B BACTEC bottle; Johnston Laboratories, Inc., Towson, Md.). We used blood agar plates (tryptic soy agar plus 5% defibrinated sheep blood) and MacConkey agar plates (Hy Laboratories, Kiryat Weizman, Rehovot, Israel). Colonies on blood and MacConkey agars were 1 mm in diameter at 24 h, white, smooth, and nonhemolytic. They grew at different temperatures in the range of 25 to 40°C. Morphologically, gram-negative short and long coccobacilli were observed in pairs. The bacteria were nonmotile and showed the following properties: catalase positive, oxidase negative, positive growth on MacConkey agar, nitrate reduction negative, urease negative, citrate negative. The bacteria were tested for fermentation with 10% glucose, fructose, galactose, mannose, shannose, xylose, lactose, sucrose, meltose, mannitol, and lactose; no acid was produced from those carbohydrates. The above-described qualities indicated that the bacteria isolated in repeated blood cultures in the two patients were A. calcoaceticus subsp. lwoffi (10) . In vitro susceptibility was tested by the method of Bauer et al. (1) . Disks contained gentamicin (11 ,ug) and cefotaxime (30 ,ug) . The antibacterial activity of the serum of both patients against the infective microorganism was determined by the serum bactericidal test (15) (Hy Laboratories). Serum bactericidal titers were determined 30 min before the first morning dose of cefotaxime and gentamicin for the trough level and 30 min after this dose for the peak level. The peak serum bactericidal titers in both patients ranged from 1:32 to 1:128, and trough levels ranged from 1:16 to 1:128.
Discussion. The incidence of PVE after cardiac valve replacement is reported between 1 and 9.4% and carries a high mortality rate ranging between 35 and 69% (5, 8, 14, 16) .
The organisms most frequently involved in PVE are Staphylococcus spp. and Streptococcus spp. (7, 8, 11, 14, 16) . Acinetobacter spp. have only rarely been associated with PVE; only four cases have been reported in the medical literature (2, 13, 17) . Two of these cases were caused by A. calcoaceticus subsp. lwoffi (2, 17) .
The time interval between the valve replacement and the occurrence of Acinetobacter PVE in the four reported cases (2, 13, 17) and the present two patients ( (13, 17) , kanamycin (2), tetracycline (13) , methicillin (13, 17) , penicillin (2, 13) , and colistin (17) , whereas our patients were successfully treated with cefotaxime and gentamicin because of the susceptibility of the subspecies. This regimen of treatment was not mentioned as being successful in the treatment of Acinetobacter infection in general or in A. calcoaceticus subsp. lwoffi in a recent report by O'Connel et al. (9) . Jones and Thornsberry (6) found a moderate susceptibility of A. calcoaceticus subsp. anitratus to cefotaxime but a good susceptibility of A. calcoaceticus subsp. lwoffi to the same antibiotic (MIC for 50% of strains tested, 1 ptg/ml; MIC for 90% of strains tested, 2 jtg/ml). Similar findings were reported by Jorgensen et al. (7) . As to the relatively low doses of cefotaxime used in our patients (3 g per day), the high serum bactericidal titers demonstrated that the cefotaxime dosage was sufficient in these patients. Serum bactericidal titers were determined on day 3 of treatment; the high titers indicated a good therapeutic effect which was similar to the good clinical course. Recently, increased resistance of Acinetobacter spp. to gentamicin has been documented in up to 30% of isolates tested (3). Amikacin and tobramycin may also be effective in the treatment of Acinetobacter infections; in one study (9a) up to 96 and 86%, respectively, of Acinetobacter isolates were susceptible in vitro to the above-mentioned drugs.
The prognosis of Acinetobacter PVE is good; none of the six patients required prosthetic valve replacement in the course of PVE, and only one patient (17) of the six died of infection, whereas five patients, including the present two patients, survived the PVE. This good prognosis in Acinetobacter PVE is probably due to the low pathogenicity and low virulence (4) of this organism and is in contrast to high PVE mortality rates caused by other organisms; mortality rates range, according to different authors, between 35 and 69% (8, 11, 14, 16) . Some authors (8, 14) suggest that in view of the high mortality rate of PVE, early replacement of the infected prosthesis should be considered in all patients with PVE, except those with streptococcal PVE. According to our two patients and the four cases reported previously (2, 13, 17) , Acinetobacter PVE may have a better prognosis than other bacterial PVE. Intensive antibiotic treatment, rather than early valve replacement, is indicated, provided the functional class of heart failure is not advanced.
